RECRUITING

Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients

Talk to us

Conditions

StrokeHemorrhagic Stroke

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic stroke). Stroke is a medical emergency and must be quickly diagnosed and treated. Computed tomography (CT) or magnetic resonance imaging (MRI) scans are commonly used to diagnose stroke, but they are not always readily available. EMVision has developed the emu™ Brain Scanner, a helmet-like device which scans the head using ultra-high frequency radio signals. It is portable and easy to use, making it more accessible than CT or MRI machines. Easier access to the EMVision emu™ Brain Scanner may reduce the time taken to diagnose stroke, leading to faster treatment and better health outcomes. It is the purpose of this study in the first instance to determine the accuracy of the EMVision emu™ Brain Scanner in the detection of haemorrhagic stroke.

Official Title

Multi-Center, Prospective, Consecutive, Paired Diagnosis, Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients

Quick Facts

Study Start:2025-03-26
Study Completion:2026-11-28
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06999122

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:22 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Adults ≥22 years of age
  2. 2. Presenting to hospital with acute neurological deficit suspected to be stroke and within 12 hours of symptom onset
  3. 3. The use of the EMVision emu™ Brain Scanner will not delay the treatment of the patient
  4. 4. CT or MRI brain imaging following clinical evaluation in Emergency Department per standard of care
  5. 5. Head size deemed suitable for scanning with the EMVision emu™ Brain Scanner -
  1. 1. Has received treatment for current (suspected) stroke event prior to initial CT/MRI scan OR EMVision emu™ Brain Scanner scan (such as thrombolysis)
  2. 2. Contraindication to neuroimaging, such as a contrast allergy or other condition that prohibits CT, MRI and/or angiography
  3. 3. Presence of any implanted electro-stimulating devices in the head and neck
  4. 4. Presence of any metallic implants in the cranial vault or surrounding bones/tissue (Note that metallic objects distant from the scan area, such as dental implants, nasal piercing etc., are acceptable)
  5. 5. Presence of an intracranial pressure monitor or any other similar sensor that may compromise the placement of the investigational device
  6. 6. Inability to wear the investigational device (skin lesions on scalp, obvious recent blunt or penetrating injury to head, previous intracranial surgeries, neck injury etc.)
  7. 7. Unable to lie still for the duration of the scan
  8. 8. Pregnant or breastfeeding
  9. 9. Any other condition or symptoms preventing the participant from entering the study, according to the investigator´s judgment -

Contacts and Locations

Study Contact

Christian Wight, PhD
CONTACT
61 (0) 490 109 797
cwight@emvision.com.au
Sadie Burnham
CONTACT
7742078910
sburnham@vastrax.com

Principal Investigator

Reade De Leacy, MBBS(Hons) FRANZCR
PRINCIPAL_INVESTIGATOR
Associate Professor of Neurosurgery and Radiology Director of Neurointerventional Spine Site Director Cerebrovascular Services Mount Sinai Queens Co-director Neuroendovascular Surgery Fellowship Department of Neurosurgery Mount Sinai Health System
Angela Dos Santos, PhD
PRINCIPAL_INVESTIGATOR
Melbourne Health

Study Locations (Sites)

Mayo Jacksonville
Jacksonville, Florida, 32224
United States
UTHealth
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: EMVision Medical Devices Ltd

  • Reade De Leacy, MBBS(Hons) FRANZCR, PRINCIPAL_INVESTIGATOR, Associate Professor of Neurosurgery and Radiology Director of Neurointerventional Spine Site Director Cerebrovascular Services Mount Sinai Queens Co-director Neuroendovascular Surgery Fellowship Department of Neurosurgery Mount Sinai Health System
  • Angela Dos Santos, PhD, PRINCIPAL_INVESTIGATOR, Melbourne Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-26
Study Completion Date2026-11-28

Study Record Updates

Study Start Date2025-03-26
Study Completion Date2026-11-28

Terms related to this study

Additional Relevant MeSH Terms

  • Stroke
  • Hemorrhagic Stroke